Skip to content
Roboearth – Lifestyle
Author:
Quantum BioPharma
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis
March 26, 2026
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd
March 23, 2026
Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering
March 20, 2026
Quantum BioPharma Provides Corporate Update
March 11, 2026
Quantum BioPharma Provides Corporate Update
March 10, 2026
←
Previous Page
1
2